Company Information

SMS PHARMACEUTICALS LTD.

NSE : SMSPHARMABSE : 532815ISIN CODE : INE812G01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE206.15-0.45 (-0.22 %)
PREV CLOSE ( ) 206.60
OPEN PRICE ( ) 202.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 148461
TODAY'S LOW / HIGH ( )200.55 207.35
52 WK LOW / HIGH ( )73.15 217.6
NSE206.25-0.25 (-0.12 %)
PREV CLOSE( ) 206.50
OPEN PRICE ( ) 202.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 206.25 (27)
VOLUME 435433
TODAY'S LOW / HIGH( ) 201.00 207.25
52 WK LOW / HIGH ( )73.15 218
ChairmanRamesh Babu Potluri
Managing DirectorRamesh Babu Potluri
Company SecretaryThirumalesh Tumma
Non Executive Independent DirectorShravan Kudaravalli
Sarvepalli Srinivas
P Sarath Kumar
T Neelaveni
Whole Time DirectorVamsi Krishna Potluri
Incorporation Year : 14-12 1987

Registered Office :

Address : Plot No. 72, H. No. 8-2-334 / 3 & 4,Road No. 5, Opp. Sbi Executive Enclave,Banjara Hills Hyderabad,
Telangana-500034 .

Phone : 040 2525 9999

Email :  info@smspharma.com 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.